Приказ основних података о документу
Placenta-specific plasma miR518b is a potential biomarker for preeclampsia
dc.creator | Munjas, Jelena | |
dc.creator | Sopić, Miron | |
dc.creator | Joksić, Ivana | |
dc.creator | Prosenc Zmrzljak, Ursula | |
dc.creator | Karadžov-Orlić, Nataša | |
dc.creator | Košir, Rok | |
dc.creator | Egić, Amira | |
dc.creator | Miković, Željko | |
dc.creator | Ninić, Ana | |
dc.creator | Spasojević-Kalimanovska, Vesna | |
dc.date.accessioned | 2020-06-12T10:06:33Z | |
dc.date.available | 2020-06-12T10:06:33Z | |
dc.date.issued | 2020 | |
dc.identifier.issn | 0009-9120 | |
dc.identifier.uri | https://farfar.pharmacy.bg.ac.rs/handle/123456789/3602 | |
dc.description.abstract | Introduction: MicroRNAs have a significant role in the pathogenesis of preeclampsia. Circulating microRNAs could represent a potential biomarker for preeclampsia. The aim of this study was to evaluate plasma miR210-3p and miR518b in preeclampsia and healthy pregnancy for the first time by digital droplet PCR (ddPCR). Methods: Thirty-six pregnant women (seventeen healthy pregnancies, nineteen preeclampsia patients) were involved from the Clinic for Gynaecology and Obstetrics “Narodni front” in Belgrade, Serbia. Plasma miR210-3p, miR518b and cel-miR-39 as a spike-in control were measured by ddPCR. Results: MiR518b was significantly elevated in preeclampsia compared to a healthy pregnancy (P = 0.034; 0.302(0.217–0.421) vs. 0.171(0.110–0.266)). MiR210-3p showed no significant difference between the two groups (P = 0.951). The adjustment of miR518b was made for a gestational age and smoking status and the difference between the preeclampsia and healthy pregnancy group was more significant (P = 0.026; 0.300(0.216–0.419) vs. 0.172(0.121–0.245)). Plasma miR-518b was significantly higher in the group of preeclampsia patients with proteinuria above the 75th percentile for the group (P=0.033), in women who smoked (P=0.039), and was positively related to uric acid in preeclampsia (P = 0.018, r = 0.536). Plasma miR518b was able to significantly discriminate between preeclampsia and healthy pregnancy, yielding AUC of 0.712 (95%CI:0.539–0.891), P = 0.028. Conclusions: In this study plasma microRNA were measured for the first time in preeclampsia and healthy pregnancies with ddPCR. Placenta-specific miR-518b could serve as a potential biomarker for discriminating preeclampsia and healthy pregnancy, which should be confirmed on a larger study population. This study has failed to confirm the same potential for miR210-3p. | en |
dc.publisher | Elsevier | |
dc.relation | info:eu-repo/grantAgreement/MESTD/Basic Research (BR or ON)/175035/RS// | |
dc.relation | ddPCR Grant challenge initiative from Labena Ltd., Slovenia | |
dc.relation.isreferencedby | https://farfar.pharmacy.bg.ac.rs/handle/123456789/3669 | |
dc.rights | restrictedAccess | |
dc.source | Clinical Biochemistry | |
dc.subject | Digital droplet PCR | |
dc.subject | miR210-3p | |
dc.subject | miR518b | |
dc.subject | Preeclampsia | |
dc.title | Placenta-specific plasma miR518b is a potential biomarker for preeclampsia | en |
dc.type | article | |
dc.rights.license | ARR | |
dcterms.abstract | Муњас, Јелена; Сопић, Мирон; Јоксић, Ивана; Егић, Aмира; Миковић, Жељко; Нинић, Aна; Спасојевић-Калимановска, Весна; Просенц Змрзљак, Урсула; Караджов-Орлић, Наташа; Кошир, Рок; Плацента-специфиц пласма миР518б ис а потентиал биомаркер фор преецлампсиа; | |
dc.citation.volume | 79 | |
dc.citation.spage | 28 | |
dc.citation.epage | 33 | |
dc.citation.rank | M22 | |
dc.description.other | This article has been corrected. Link to the correction: [https://farfar.pharmacy.bg.ac.rs/handle/123456789/3669] | |
dc.identifier.wos | 000530708900005 | |
dc.identifier.doi | 10.1016/j.clinbiochem.2020.02.012 | |
dc.identifier.scopus | 2-s2.0-85081737467 | |
dc.type.version | publishedVersion |